RU2018138503A - Диагностические способы при выборе персонифицированного способа лечения рака - Google Patents
Диагностические способы при выборе персонифицированного способа лечения рака Download PDFInfo
- Publication number
- RU2018138503A RU2018138503A RU2018138503A RU2018138503A RU2018138503A RU 2018138503 A RU2018138503 A RU 2018138503A RU 2018138503 A RU2018138503 A RU 2018138503A RU 2018138503 A RU2018138503 A RU 2018138503A RU 2018138503 A RU2018138503 A RU 2018138503A
- Authority
- RU
- Russia
- Prior art keywords
- cells
- paragraphs
- tissue culture
- aggregates
- aggregation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 17
- 206010028980 Neoplasm Diseases 0.000 title claims 11
- 201000011510 cancer Diseases 0.000 title 1
- 238000002405 diagnostic procedure Methods 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 20
- 210000001519 tissue Anatomy 0.000 claims 14
- 238000004220 aggregation Methods 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 210000000130 stem cell Anatomy 0.000 claims 4
- 238000004114 suspension culture Methods 0.000 claims 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 210000002950 fibroblast Anatomy 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 230000035899 viability Effects 0.000 claims 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
- 208000007660 Residual Neoplasm Diseases 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 230000003833 cell viability Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000002744 extracellular matrix Anatomy 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (21)
1. Трехмерный (3D) агрегат культуры ткани из клеток, полученных из пробы опухолевой ткани, где ≤30% от общего числа клеток представляют собой клетки, способные препятствовать повторной агрегации; при этом указанный агрегат не содержит искусственный каркас.
2. 3D агрегат культуры ткани по п. 1, отличающийся тем, что клетки, способные препятствовать повторной агрегации, представляют собой лимфоидные клетки.
3. 3D агрегат культуры ткани по п. 1 или 2, отличающийся тем, что клетки, способные препятствовать повторной агрегации, представляют собой CD45+.
4. Способ получения 3D агрегата культуры ткани, включающий:
(a) получение адаптированной популяции клеток из пробы опухолевой ткани путем уменьшения количества клеток, способных препятствовать повторной агрегации, до ≤30% от общего числа клеток; и
(b) получение суспензионной культуры, содержащей клетки указанной адаптированной клеточной популяции, культуральную среду и, необязательно, фибробласты; при отсутствии искусственного каркаса.
5. Способ по п. 1, отличающийся тем, что количество фибробластов в исходной суспензионной культуре составляет 5-50% от общего количества клеток.
6. Способ по п. 4 или 5, отличающийся тем, что количество клеток из адаптированной клеточной популяции в исходной суспензионной культуре составляет от 2×104 до 8×106.
7. Способ по любому из пп. 4-6, отличающийся тем, что количество клеток, способных препятствовать повторной агрегации, уменьшают с помощью иммунологического способа разделения частиц или способа разделения путем сортировки клеток.
8. Способ по любому из пп. 4-7, отличающийся тем, что внеклеточный матрикс в трехмерных (3D) агрегатах культуры опухолевой ткани продуцируют только сами клетки.
9. Способ по любому из пп. 4-8, отличающийся тем, что клетки, способные препятствовать повторной агрегации, представляют собой лимфоидные клетки.
10. Способ по любому из пп. 4-9, отличающийся тем, что клетки, способные препятствовать повторной агрегации, представляют собой CD45+.
11. Применение 3D агрегатов культуры ткани по любому из пп. 1-3 или полученных способом по любому из пп. 4-10 для оценки эффективности противоопухолевого лечения.
12. Способ оценки эффективности противоопухолевого лечения путем измерения влияния указанного лечения на жизнеспособность трехмерных (3D) агрегатов культуры опухолевой ткани.
13. Способ по п. 12, отличающийся тем, что указанные 3D агрегаты культуры опухолевой ткани представляют собой 3D агрегаты культуры ткани по любому из пп. 1-3 или получены способом по любому из пп. 4-9.
14. Способ по п. 12 или 13, отличающийся тем, что жизнеспособность 3D агрегатов культуры опухолевой ткани измеряют с использованием анализа жизнеспособности клеток.
15. Способ по любому из пп. 12-14, дополнительно включающий определение клеточного состава 3D агрегатов культуры опухолевой ткани с помощью анализа маркеров клеточной поверхности с использованием проточной цитометрии.
16. Способ по любому из пп. 12-15, дополнительно включающий оценку чувствительности остаточных раковых стволовых клеток к лекарственному средству после обработки первым противоопухолевым средством путем
(i) выделения опухолевых стволовых клеток с использованием комбинаций маркеров клеточной поверхности;
(ii) повторной агрегации выделенных опухолевых стволовых клеток в 3D-ткань; а также
(iii) приведения агрегированных опухолевых стволовых клеток в контакт со вторым противоопухолевым средством, при этом указанное первое противоопухолевое средство и указанное второе противоопухолевое средство отличаются друг от друга.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201605759 | 2016-04-04 | ||
| GB1605759.8 | 2016-04-04 | ||
| PCT/EP2017/058034 WO2017174609A1 (en) | 2016-04-04 | 2017-04-04 | Diagnostic methods for patient specific therapeutic decision making in cancer care |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018138503A true RU2018138503A (ru) | 2020-05-12 |
| RU2018138503A3 RU2018138503A3 (ru) | 2020-08-18 |
Family
ID=58609360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018138503A RU2018138503A (ru) | 2016-04-04 | 2017-04-04 | Диагностические способы при выборе персонифицированного способа лечения рака |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190128870A1 (ru) |
| EP (1) | EP3440199A1 (ru) |
| JP (1) | JP2019513418A (ru) |
| KR (1) | KR20190003549A (ru) |
| CN (1) | CN109563486A (ru) |
| AU (1) | AU2017245629A1 (ru) |
| CA (1) | CA3019873A1 (ru) |
| IL (1) | IL262121A (ru) |
| MX (1) | MX2018012143A (ru) |
| PH (1) | PH12018502147A1 (ru) |
| RU (1) | RU2018138503A (ru) |
| SG (1) | SG11201808762XA (ru) |
| WO (1) | WO2017174609A1 (ru) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| ES2860423T3 (es) | 2014-05-28 | 2021-10-05 | Childrens Hospital Med Ct | Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida |
| CA2963704A1 (en) | 2014-10-17 | 2016-04-21 | Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
| CN116790476A (zh) | 2016-05-05 | 2023-09-22 | 儿童医院医疗中心 | 用于体外制造胃底组织的方法和与其相关的组合物 |
| EP3534907A4 (en) | 2016-11-04 | 2020-06-24 | Children's Hospital Medical Center | COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASES |
| CA3045145A1 (en) | 2016-12-05 | 2018-06-14 | Children's Hospital Medical Center | Colonic organoids and methods of making and using same |
| US12281334B2 (en) | 2017-04-14 | 2025-04-22 | Children's Hospital Medical Center | Multi donor stem cell compositions and methods of making same |
| WO2019074793A1 (en) | 2017-10-10 | 2019-04-18 | Children's Hospital Medical Center | OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME |
| EP3727394A4 (en) | 2017-12-21 | 2021-09-08 | Children's Hospital Medical Center | DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF |
| CN108130313B (zh) * | 2017-12-28 | 2021-04-30 | 杭州枫霖科技有限公司 | 一种基于生物3d打印构建三维胶质瘤组织的方法 |
| CA3106634A1 (en) | 2018-07-26 | 2020-01-30 | Children's Hospital Medical Center | Hepato-biliary-pancreatic tissues and methods of making same |
| US12428622B2 (en) | 2018-09-12 | 2025-09-30 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| KR102030127B1 (ko) | 2019-01-10 | 2019-10-08 | 주식회사 보타닉센스 | 운데칸 또는 운데칸알을 유효성분으로 포함하는 항알러지, 아토피 피부염 개선, 또는 피부 재생용 조성물 |
| AU2020283048A1 (en) | 2019-05-31 | 2021-12-23 | Children's Hospital Medical Center | Shaped organoid compositions and methods of making same |
| US12497597B2 (en) | 2019-05-31 | 2025-12-16 | Children's Hospital Medical Center | Methods of generating and expanding hematopoietic stem cells |
| DE102019132865B4 (de) * | 2019-12-03 | 2022-01-20 | Precomb Therapeutics Ag | Verfahren und vorrichtung für die analyse von gewebeproben |
| CN111690615B (zh) * | 2020-06-12 | 2022-10-25 | 江苏信安佳医疗科技有限公司 | 一种鼻咽癌类器官专用培养基及无支架培养方法 |
| KR102577816B1 (ko) * | 2022-06-08 | 2023-09-12 | 차의과학대학교 산학협력단 | 암 미세환경 모사 췌장암 오가노이드의 제조방법 및 이의 용도 |
| CN117625541B (zh) * | 2024-01-26 | 2024-04-02 | 零壹人工智能科技研究院(南京)有限公司 | 一种脑胶质瘤类器官构建方法及药敏检测方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0900819A2 (en) * | 2009-05-05 | 2011-01-28 | Pecsi Tudomanyegyetem | Lung tissue culture |
| EP2450707B1 (en) * | 2010-11-04 | 2016-04-27 | University of Pécs | Lung tissue model |
| JP5774496B2 (ja) | 2010-01-19 | 2015-09-09 | 株式会社ルネッサンス・エナジー・インベストメント | 癌組織由来細胞塊または癌細胞凝集塊の培養方法、評価方法および保存方法 |
| GB201100180D0 (en) * | 2011-01-06 | 2011-02-23 | Capsant Neurotechnologies Ltd | Tumour cell and tissue culture |
| US20140128272A1 (en) | 2012-11-08 | 2014-05-08 | Osaka Prefectural Hospital Organization | Method for Inducing Dormancy of Cancer Tissue-Derived Cell Mass and Method for Evaluating Treating Means with the Use of Cancer-Tissue-Derived Cell Mass |
| US10545133B2 (en) | 2013-05-13 | 2020-01-28 | The Johns Hopkins University | Molecular signatures of invasive cancer subpopulations |
| US20160123960A1 (en) | 2013-06-10 | 2016-05-05 | Millennium Pharmaceuticals, Inc. | Method for preparing three-dimensional, organotypic cell cultures and uses thereof |
| WO2015073724A1 (en) | 2013-11-15 | 2015-05-21 | Molecular Response, Llc | 3d cell culture and ex vivo drug testing methods |
| TWI486451B (zh) * | 2013-12-11 | 2015-06-01 | Ind Tech Res Inst | 經分離之人類肝癌細胞株及化合物篩選方法 |
| TWI461535B (zh) * | 2013-12-11 | 2014-11-21 | Ind Tech Res Inst | 經分離之人類肝癌細胞株及化合物篩選方法 |
| CN106574242B (zh) | 2014-06-20 | 2021-01-15 | 新泽西鲁特格斯州立大学 | 源自单细胞的类器官 |
| WO2016022830A1 (en) | 2014-08-06 | 2016-02-11 | Oregon Health & Science University | Three-dimensional bioprinted pancreatic tumor model |
| CN105062973B (zh) * | 2015-07-22 | 2018-04-17 | 中山大学 | 一株携带tp53突变的hpv阴性阴茎鳞癌细胞系及其用途 |
-
2017
- 2017-04-04 KR KR1020187032071A patent/KR20190003549A/ko not_active Ceased
- 2017-04-04 AU AU2017245629A patent/AU2017245629A1/en not_active Abandoned
- 2017-04-04 CA CA3019873A patent/CA3019873A1/en not_active Abandoned
- 2017-04-04 EP EP17718845.5A patent/EP3440199A1/en not_active Withdrawn
- 2017-04-04 WO PCT/EP2017/058034 patent/WO2017174609A1/en not_active Ceased
- 2017-04-04 JP JP2019503628A patent/JP2019513418A/ja active Pending
- 2017-04-04 CN CN201780034789.4A patent/CN109563486A/zh active Pending
- 2017-04-04 SG SG11201808762XA patent/SG11201808762XA/en unknown
- 2017-04-04 US US16/091,434 patent/US20190128870A1/en not_active Abandoned
- 2017-04-04 RU RU2018138503A patent/RU2018138503A/ru not_active Application Discontinuation
- 2017-04-04 MX MX2018012143A patent/MX2018012143A/es unknown
-
2018
- 2018-10-04 PH PH12018502147A patent/PH12018502147A1/en unknown
- 2018-10-04 IL IL262121A patent/IL262121A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018012143A (es) | 2019-10-09 |
| EP3440199A1 (en) | 2019-02-13 |
| SG11201808762XA (en) | 2018-11-29 |
| JP2019513418A (ja) | 2019-05-30 |
| AU2017245629A1 (en) | 2018-11-22 |
| KR20190003549A (ko) | 2019-01-09 |
| PH12018502147A1 (en) | 2019-07-15 |
| IL262121A (en) | 2018-11-29 |
| US20190128870A1 (en) | 2019-05-02 |
| CA3019873A1 (en) | 2017-10-12 |
| CN109563486A (zh) | 2019-04-02 |
| WO2017174609A1 (en) | 2017-10-12 |
| RU2018138503A3 (ru) | 2020-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018138503A (ru) | Диагностические способы при выборе персонифицированного способа лечения рака | |
| JP7506011B2 (ja) | 心筋細胞シート | |
| Kwon et al. | Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas | |
| DE13731071T1 (de) | Verfahren zur Quantifizierung von Immunzellen in Tumorgewebe und dessen Anwendungen | |
| JP2013504303A5 (ru) | ||
| Al-Samadi et al. | Crosstalk between tongue carcinoma cells, extracellular vesicles, and immune cells in in vitro and in vivo models | |
| Kastrinaki et al. | Mesenchymal stem cells in immune‐mediated bone marrow failure syndromes | |
| KR20190096415A (ko) | 3차원 시험관 내 폐포 폐 모델, 상기 모델의 제조 방법, 및 흡입성 제품의 민감화 효과를 측정하고/하거나 예측하기 위한 이의 용도 | |
| CN106244553A (zh) | 循环肿瘤细胞的分离和检测方法 | |
| DE102012213838A1 (de) | Verfahren zur Kultivierung einer Subpopulation zirkulierender epithelialer Tumorzellen aus einer Körperflüssigkeit | |
| Chowdhry et al. | Quantitative estimation of AgNORs in normal, dysplastic and malignant oral mucosa | |
| Udenze et al. | Offspring affected with in utero Zika virus infection retain molecular footprints in the bone marrow and blood cells | |
| Steimberg et al. | In vitro modeling of tissue-specific 3D microenvironments and possibile application to pediatric cancer research | |
| US20080254480A1 (en) | Microcytoxicity assay by pre-labeling target cells | |
| Kagawa et al. | Localized pulmonary histiocytic sarcomas in Pembroke Welsh Corgi | |
| Vainio et al. | Studies on kidney tubulogenesis VI. Survival and nucleic acid metabolism of differentiating mouse metanephrogenic mesenchyme in vitro | |
| Wolff et al. | Peripheral blood stem cell transplants do not result in endometrial stromal engraftment | |
| GB2485816A (en) | In vitro model for the prediction of immunogenicity, hypersensitivity or allergenicity | |
| Bizzari et al. | The estimation of self-renewal in the clonogenic cells of human solid tumours: a comparison of secondary plating efficiency and colony size | |
| Neri et al. | Expansion of effector memory CD27+ T cells and tolerogenic type 2 classical dendritic cells regulate myeloma patients’ sensitivity to daratumumab & IMiDs | |
| Chistiakova et al. | Influence of human fetal mesenchymal stem cells on glioma cell proliferation. A consequence of cellular crosstalk | |
| US20250043245A1 (en) | Method of producing an immune cell that responds to a cancer-associated antigen | |
| Singh | Statistically Analyzing the Biodiversity and Water Quality of Loudoun County Local Streams | |
| Hintz | Variations in populations and cell dimensions of phytoplankton in the island region of western Lake Erie | |
| Quiñones-Torrelo et al. | PB2100 MULTI-BIOMARKER NORMALIZATION OF MM SERUM PATIENTS AS POSSIBLE GATEWAY FOR BONE MARROW MRD BY MULTIPARAMETER FLOW CYTOMETRY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210702 |